ALSA Ventures
2026-09-01alsaventures.com
Overview
What they do
ALSA Ventures is a specialist investment firm dedicated to the life sciences sector, specifically focusing on novel therapeutics. Founded in 2019 by Alek Safarian, the former CEO of the global contract research organisation (CRO) Novotech, the firm leverages deep operational and clinical development expertise to support portfolio companies. Unlike generalist VCs, ALSA often takes a hands-on approach to company formation and clinical strategy, exemplified by their 'Eclipse' accelerator program which partners with ICON Plc to fast-track preclinical assets to first-in-human trials.
alsaventures.com
What they look for
ALSA Ventures invests in 'tomorrow’s breakthroughs today,' focusing specifically on novel therapeutics (drugs) rather than devices or diagnostics. They target companies with strong mechanistic rationale and clear translational paths to clinical data. They look for genuine breakthrough potential from discovery stage to late preclinical development.
alsaventures.com
Stage
Seed
alsaventures.com
Sectors
Healthcare
alsaventures.com
Based
London, GB
alsaventures.com
Sources
2026-09-01alsaventures.comALSA Ventures is an international life science investor focused on novel therapeutics.
2026-09-01alsaventures.comOur investment approach is primarily focused around therapeutics. We look for novel drugs and…
Portfolio, cheque size and the rest
The 3 companies they have backed that we can see, the cheque they write, and whether they are deploying right now.
Start free, no cardFree accounts see every record.